Omeicos Therapeutics GmbH is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, first-in-class small molecule therapeutics. These are synthetic analogues of omega-3 fatty acid metabolites, specifically epoxyeicosanoids, designed to be metabolically stable. The company's research targets severe inflammatory, cardiovascular, and ophthalmic diseases, aiming to address significant unmet medical needs with innovative treatments. Omeicos originated as a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin.
Serves as the central hub for research and development, clinical trial management, strategic planning, corporate administration, and alliance management.
Located within the Campus Berlin-Buch, a leading science and biotechnology park, providing access to state-of-the-art laboratory facilities, shared research infrastructure, and a collaborative scientific ecosystem.
A science-driven, innovative, and collaborative work environment. Employees are typically highly qualified professionals focused on pioneering research and development of novel therapeutics. The culture emphasizes teamwork, scientific rigor, and a commitment to addressing significant medical challenges.
The Berlin headquarters is pivotal as the company's main operational and strategic center, driving all R&D activities from discovery through clinical development, and fostering collaborations within the rich Berlin biotech ecosystem.
Omeicos Therapeutics GmbH, while headquartered in Germany, conducts clinical trials and research collaborations that may span multiple countries, particularly within Europe and North America, to advance its therapeutic pipeline. Its global activities support drug development, regulatory affairs, and preparations for potential future commercialization.
Robert-Roessle-Str. 10, Building D79
Berlin
Berlin
Germany
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, OMEICOS Therapeutics GmbH' leadership includes:
OMEICOS Therapeutics GmbH has been backed by several prominent investors over the years, including:
Dr. Karen Uhlmann, former CFO/CBO, departed from Omeicos Therapeutics in late 2023. Public information on other specific executive hires in the immediate last 12 months is limited.
Discover the tools OMEICOS Therapeutics GmbH uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for Omeicos Therapeutics GmbH likely utilize a combination of the employee's first initial and last name, or full name, with the company domain '@omeicos.com'.
[first_initial].[last]@omeicos.com
Format
r.fischer@omeicos.com
Example
80%
Success rate
Omeicos Therapeutics Website • January 23, 2024
Omeicos Therapeutics announced its participation and presentation at the Angiogenesis, Exudation, and Degeneration 2024 conference, showcasing recent advancements in its ophthalmic programs and specifically highlighting data related to OMT-28....more
Omeicos Therapeutics Website • June 27, 2023
Omeicos Therapeutics announced positive topline data from its Phase 2a CLIOMACS clinical trial evaluating OMT-28 for the treatment of patients with persistent macular edema due to retinal vein occlusion (RVO) or diabetes (DME). The study met its primary safety and tolerability endpoints, and OMT-28 demonstrated promising efficacy signals, supporting its further clinical development....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including OMEICOS Therapeutics GmbH, are just a search away.